Max Chaffanet
Overview
Explore the profile of Max Chaffanet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guille A, Adelaide J, Finetti P, Andre F, Birnbaum D, Mamessier E, et al.
Brief Bioinform
. 2025 Jan;
26(1).
PMID: 39828270
By identifying somatic mutations, whole-exome sequencing (WES) has become a technology of choice for the diagnosis and guiding treatment decisions in many cancers. Despite advances in the field of somatic...
2.
Udu-Ituma S, Adelaide J, Le T, Omabe K, Finetti P, Paris C, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514116
The luminal B molecular subtype of breast cancers (BC) accounts for more than a third of BCs and is associated with aggressive clinical behavior and poor prognosis. The use of...
3.
Laberthonniere C, Delourme M, Chevalier R, Dion C, Ganne B, Hirst D, et al.
Nucleic Acids Res
. 2023 Jun;
51(14):7269-7287.
PMID: 37334829
Many genetic syndromes are linked to mutations in genes encoding factors that guide chromatin organization. Among them, several distinct rare genetic diseases are linked to mutations in SMCHD1 that encodes...
4.
Velazquez C, Orhan E, Tabet I, Fenou L, Orsetti B, Adelaide J, et al.
Front Oncol
. 2023 Apr;
13:1125021.
PMID: 37007122
Background: About 15% of Triple-Negative-Breast-Cancer (TNBC) present silencing of the promoter methylation and are assumed to be Homologous Recombination Deficient (HRD). -methylated (-Me) TNBC could, thus, be eligible to treatment...
5.
Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, et al.
Front Oncol
. 2022 Aug;
12:946257.
PMID: 35965534
Introduction: The poor prognosis of ovarian carcinoma (OvC) is due to the advanced stage at diagnosis, a high risk of relapse after first-line therapies, and the lack of efficient treatments...
6.
de Nonneville A, Salas S, Bertucci F, Sobinoff A, Adelaide J, Guille A, et al.
EMBO Mol Med
. 2022 Aug;
14(10):e15859.
PMID: 35920001
In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α-thalassemia/mental retardation syndrome X-linked (ATRX) gene is mutated...
7.
Neron M, Guille A, Allegre L, Colombo P, Leaha C, Adelaide J, et al.
J Pers Med
. 2022 May;
12(5).
PMID: 35629078
Hormone therapy (HT) is an effective treatment for metastatic endometrial carcinoma (mEC), with limited toxicity and low cost. We focused on molecular analysis of mECs treated by HT and, for...
8.
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
Billon E, Gravis G, Guille A, Carbuccia N, Adelaide J, Garnier S, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565404
Introduction: The prognosis of advanced urological cancers (AUC) remains unfavorable, and few data are available regarding precision medicine. Methods: the PERMED-01 prospective clinical trial assessed the impact of molecular profiling...
9.
Cabaud O, Berger L, Crompot E, Adelaide J, Finetti P, Garnier S, et al.
Mol Cancer Ther
. 2022 May;
21(7):1227-1235.
PMID: 35534238
Antibody-drug conjugates (ADC) represent a fast-growing drug class in oncology. However, ADCs are associated with resistance, and therapies able to overcome it are of utmost importance. Recently, enfortumab vedotin-ejfv (EV)...
10.
Chanez B, Chaffanet M, Adelaide J, Thomassin J, Garnier S, Carbuccia N, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-8.
PMID: 35135132
No abstract available.